

In the Claims:

1. **(Currently amended)** A composition for organ preservation, comprising an inulin type fructan as an active ingredient **in an amount effective for preservation of the organ, wherein the composition comprises:**

(a) inulin type fructan 3.5 - 300 g/L;

(b) Na⁺ 5 - 150 mM;

(c) K⁺ 5 - 150 mM;

and

(d) at least one component selected

from the group consisting of Cl⁻, HCO₃⁻,

CO₃²⁻, organic acids, and organic

acid anions 10 - 150 mM.

2. **(Original)** The composition for organ preservation according to claim 1, wherein the inulin type fructan is a mixture of two or more inulin type fructans selected from inulin type fructans having a degree of polymerization of 3 to 6.

3. **(Original)** The composition for organ preservation according to claim 1, wherein the inulin type fructan is 1-kestose.

4. **(Original)** The composition for organ preservation according to claim 1, wherein the inulin type fructan is nystose.

5. **(Cancelled)** ~~The composition for organ preservation according to claim 1, which comprises:~~

~~(a) inulin type fructan 3.5 - 300 g/L;~~

~~(b) Na⁺ 5 - 150 mM;~~

~~(c) K^+ 5 - 150 mM;~~

~~and~~

~~(d) at least one component selected~~

~~from the group consisting of Cl^- , HCO_3^- ,~~

~~CO_3^{2-} , organic acids, and organic~~

~~acid anions 10 - 150 mM.~~

6. **(Currently amended)** The composition for organ preservation according to claim **[[5]] 1**, which further comprises at least one of:

(e) Mg^{2+} 0 - 20 mM;

(f) Ca^{2+} 0 - 5 mM;

(g) $H_2PO_4^-$ and/or HPO_4^{2-} 0 - 150 mM;

and

(h) hydroxyethyl starch 0 - 100 g/L.

7. **(Currently Amended)** The composition for organ preservation according to claim 1, for suppressing or improving hypofunction of and damage to an organ **which possibly occur** during an organ transplantation process.

8. **(Previously presented)** A method for preserving an organ, comprising the step of bringing an effective amount for organ preservation of the composition for organ preservation according to claim 1 into contact with an organ.

9. **(Original)** The method according to claim 8, wherein said contact is carried out by perfusing the organ with the composition for organ preservation.

10. **(Currently Amended)** A method for suppressing or improving hypofunction of and damage to an organ ~~which possibly occur~~ during an organ transplantation process,
said method comprising the step of bringing an effective amount for suppression or improvement of the composition for organ preservation according to claim 1 into contact with an organ.

11. **(Previously presented)** The method according to claim 8, wherein said organ is selected from the group consisting of kidney, liver, heart, lung, and pancreas.

12. **(Currently amended)** ~~Use of an inulin type fructan for the manufacture of~~ A method comprising making a composition for organ preservation comprising an inulin type fructan as an active ingredient in an amount effective for preservation of the organ, wherein the composition comprises:

(a) inulin type fructan 3.5 - 300 g/L;

(b) Na⁺ 5 - 150 mM;

(c) K⁺ 5 - 150 mM;

and

(d) at least one component selected
from the group consisting of Cl⁻, HCO₃⁻,

CO₃²⁻, organic acids, and organic

acid anions 10 - 150 mM.

13. **(Currently Amended)** ~~[[Use]]~~ The method according to claim 12, wherein the inulin type fructan is a mixture of two or more inulin type fructans selected from inulin type fructans having a degree of polymerization of 3 to 6.

14. **(Currently Amended) [[Use]] The method** according to claim 12, wherein the inulin type fructan is 1-kestose.
15. **(Currently Amended) [[Use]] The method** according to claim 12, wherein the inulin type fructan is nystose.
16. **(Currently Amended) [[Use]] The method** according to claim 12, wherein said composition for organ preservation is a perfusate for the organ.
17. **(Currently Amended) [[Use]] The method** according to claim 12, wherein said organ is selected from the group consisting of kidney, liver, heart, lung, and pancreas.